News for Iovance Biotherapeutics, Inc. (IOVA)

Summary Iovance Biotherapeutics Inc (IOVA), a leader in the development of tumor infiltrating lymphocyte (TIL) therapies, announced on April 23, 2025, that it w

**media[603692]**

Iovance Biotherapeutics (IOVA) sees a surge in revenue thanks to its innovative cancer therapy, Amtagvi. The company expects product revenue to reach up

There's an incredible growth story hiding in plain sight for investors who can look to the future.

Iovance Biotherapeutics (IOVA) approved inducement stock options for 50 new employees. The options cover 297,600 shares at an exercise price of $3.06. The

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc.

**media[599188]**

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Iovance Biotherapeutics Inc.

\nInvestment rationale: Innovative cell therapy solutions for cancer treatment.Market positioning: Leader in the biopharmaceutical industry.Risks and challenges:

Iovance Biotherapeutics (NASDAQ: IOVA) just might be the right kind of biotech stock. The company has already achieved success. To appreciate Iovance's opportunity, we need to first gain a basic understanding of the company's primary scientific focus.

Iovance Biotherapeutics, Inc. (IOVA) anticipates robust revenue growth by 2025. Analysts predict a potential upside of 533.61% for IOVA stock. The co

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year. Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent.

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa.,

**media[579911]**

**media[578192]**

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Here's what investors need to know about this small-cap biotech company. Iovance Biotherapeutics develops therapies that harness the power of tumor-infiltrating lymphocytes (TILs), immune cells that can target and destroy cancer cells.

The time to buy quality prospects is when the rest of the market is ignoring their value.